Advances in Lung Cancer Research from ASCO 2024

It was an exciting time at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, where significant developments in research were presented. Melissa Johnson , MD, Director, Lung Cancer Research; Executive Chair, Lung Cancer Research Executive Committee, SCRI, shares summaries of several innovative lung cancer trials that are advancing therapies.

?

ADRIATIC: Durvalumab as Consolidation Treatment for Patients with Limited-Stage Small-Cell Lung Cancer

• Presented by SCRI’s David R. Spigel, MD , FASCO, this is the first major breakthrough in this setting in decades.
• This trial proves that immunotherapy can be used to reduce deaths by 27% for patients with limited-stage small-cell lung cancer.
• This therapy helped people in the early stages of this certain type of lung cancer live 23 months longer.
• It is the first phase III trial to establish the role of immunotherapy in limited-stage small cell lung cancer, establishing a new standard of care.

?

Osimertinib After Definitive Chemoradiotherapy in Patients with Unresectable Stage III Epidermal Growth Factor Receptor-Mutated NSCLC: Primary Results of The Phase 3 LAURA Study

• In LAURA, osimertinib demonstrated a statistically significant and clinically meaningful improvement in progression free survival versus placebo by BICR in unresectable stage III EGFRm non-small cell lung cancer?(NSCLC) following definitive chemoradiotherapy.
• Osimertinib will become the new standard of care for patients with unresectable stage Ill EGFRm NSCLC who have not progressed after definitive chemoradiotherapy.

?

Lorlatinib vs Crizotinib in Treatment-Na?ve Patients with Advanced? ALK + Non-Small Cell Lung Cancer: 5-Year Progression-Free Survival and Safety from The CROWN Study

• This pivotal study showed the longest progression-free survival outcomes seen for any next generation ALK tyrosine kinase inhibitor.
• It showed nearly complete prevention of CNS metastases, which is often a serious complication of progressive ALK-positive lung cancer.
• This is among the best long-term outcomes of any TKI in lung cancer ever seen.

?

Subcutaneous Amivantamab vs Intravenous Amivantamab, Both in Combination with Lazertinib, in Refractory?EGFR-Mutated, Advanced Non-Small Cell Lung Cancer: Primary Results, Including Overall Survival, from The Global, Phase 3, Randomized Controlled PALOMA-3 Trial

• Subcutaneous amivantamab use led to safer outcomes for patient than when taken intravenously.
• There also was a suggested efficacy benefit for subcutaneous dosing versus IV, which will require further investigation to confirm.
• This is important news for patients because amivantamab can now only be given IV - and is associated with hypersensitivity reactions and other toxicities.
• To have a safe, and perhaps more effective means of delivery, changes how we help even more patients get treatment for advanced disease.
• This also raises important questions for other agents about ways to improve safety and potential efficacy through subcutaneous use.

What studies presented at ASCO were you most excited about? Comment below!

?

#ASCO24 #Research #Oncology #ScientificAdvancements #ClinicalTrials #ResearchNews #OncologyExperts

?